PSA - Stem Cell Research - Democratic For AP LangFrom:musicbanshee13Views:23 0ratingsTime:01:08More inEducation See the original post: PSA - Stem Cell Research - Democratic - Video … Continue reading →

PSA - Stem Cell Research - Republican For AP LangFrom:musicbanshee13Views:0 0ratingsTime:01:03More inEducation Read more from the original source: PSA - Stem Cell Research - Republican - Video … Continue reading →

ALAMEDA, Calif.--(BUSINESS WIRE)-- LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the launch of LifeMap Discovery (discovery.lifemapsc.com), a state-of-the-art roadmap of embryonic development and stem cell biology. The platform integrates embryonic development and stem cell biology with molecular, cellular, anatomical, and disease-related information, and provides data-mining capabilities and bioinformatics applications. LifeMap Discovery is a unique and powerful tool for research and discovery in multiple disciplines, including stem cell biology, developmental biology, disease mechanisms and etiology, and drug and therapeutic discovery and development. This new and innovative database is a central element in LifeMaps discovery platform for biomedical and stem cell research, which also includes GeneCards, the leading human gene database, and MalaCards, the human disease database. The launch of LifeMap Discovery represents a key milestone for LifeMap Sciences. The platform is a central element in the generation of near-term revenues through paid subscriptions, and is expected to drive traffic to the recently launched LifeMap BioReagents marketing portal, as well as aid in the companys therapeutic discovery activities. Near-term subscription revenues from pharmaceutical and biotechnology companies Like GeneCards and MalaCards, LifeMap Sciences is making certain aspects of LifeMap Discovery free for use to stem cell researchers … Continue reading →

Houston, TX (PRWEB) November 27, 2012 Nano3D Biosciences (N3D), a life sciences technology company that specializes in three dimensional (3D) cell culturing products for the drug discovery, toxicology and life science research markets announced today that its technology was recently used in a breakthrough stem cell study. The Bio-Assemblers fusion of magnetic levitation and nanoparticle assembly technology allows it to produce accurate 3D representation of in vivo tissue faster and easier than any other existing tools. Dr. Mikhail Kolonin, an associate professor at the University of Texas Health Science Center at Houston, and Dr. Glauco Souza of N3D authored a study that demonstrates how effective 3D cell culturing by magnetic levitation is in generating white adipose tissue organoids or adipospheres, using the Bio-Assembler. A significant breakthrough was that the 3D structures presented vascular-like structures when pre-adipocyte stem cells were co-cultured with endothelial cells: Refer to Adipose tissue engineering in three-dimensional levitation tissue culture system based on magnetic nanoparticles, as published in the journal Tissue Engineering C. We are particularly excited about the next phase of development where we will expand on this work to study the relationship between obesity and cancer using human cells within an in vitro and 3D … Continue reading →

TORONTO, ONTARIO--(Marketwire - Nov. 26, 2012) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS), announces today that consistent with the Company's corporate objective of the acquisition and development of additional stem cell-based therapies, and in order to attract the capital required to support this objective, management and the board of directors recommend the consolidation of the outstanding shares. Consolidation will permit the issuance of additional securities not currently permitted under $0.10 per share that has limited the Company's options. The consolidation is generally expected to be advantageous to the Company's corporate objectives and in attracting investors to the opportunities that may emerge from the Company's rebuilding. A meeting of shareholders will be held on December 20th, 2012 to vote on the recommendation of the board to consolidate the outstanding common shares on the basis of a ratio to be proposed by the board of directors in the range of one post-consolidation common share for each 10 to 30 outstanding pre-consolidation common shares. The meeting will be held at the Offices of McCarthy Ttrault LLP, Toronto Dominion Bank Tower, 53rd Floor, J.J. Robinette Boardroom, TD Centre, 66 Wellington Street West, Toronto, ON M5K 1E6, on December 20, 2012, at 10:00 am (Toronto … Continue reading →

Four years ago, Michigan made an important step forward for science. The state passed Proposal 2, a 2008 ballot proposal, and ended the 30-year ban on embryonic stem cell line usage in Michigan. However, little progress has been made since then, as the state has not garnered the funding necessary to support these projects. Now Michigan is falling well behind the rest of the country and is stuck looking for ways to revive a depressed economy. Michigan and the University must make stem cell research a top priority, and allow it to jump-start the science economy. In comparison to other states, Michigan has lagged behind in fundraising for stem cell research. Even after Proposal 2s passage, Michigan has been slow to enact any significant changes due to a lack of interest from private investors. According to the Detroit Free Press, California provides $300 million yearly for stem cell research, and Ohio has been providing millions for similar research. California has gone further, adding $1.6 billion in new investments, which generates about 2,739 jobs annually. Despite Michigans fundraising obstacles, the University has continued to be a leader in stem cell research. Since 2009, the University has made several significant strides. The … Continue reading →

ScienceDaily (Nov. 27, 2012) Tension is the theme running through the new consensus statement issued by the Hinxton Group, an international working group on stem cell research and regulation. Specifically, tension between intellectual property policies and scientific norms of free exchange, but also between eastern and western cultures, national and international interests, and privatized vs. nationalized health care systems. The consensus, titled Statement on Data and Materials Sharing and Intellectual Property in Pluripotent Stem Cell Science in Japan and China, was released on the Hinxton Group's website on November 19, 2012. "China and Japan are among the world's leading nations in stem cell research, but because of challenges distinct from western nations, they are dramatically underrepresented in terms of patents and licensing," says Debra Mathews, PhD, MA, assistant director of Science Programs at the Johns Hopkins Berman Institute of Bioethics and a founding member of the Hinxton Group. Mathews was one of 22 co-signers of the consensus statement. "We thought it was crucial, with the science advancing incredibly rapidly, and as intellectual property policies evolve in East Asia, to examine our 2010 global recommendations for proprietary issues in stem cell research in that regional context," Mathews says. Strengthening national stem … Continue reading →

Should patents on the products of embryonic stem cell research be allowed? The European Court of Justice said no, but the question remained unanswered in Germany - until now. The German constitution, called the Basic Law, guarantees the freedom of research. It also guarantees every human being the right to life. These two principles come into conflictwhenfacedwith the matter ofhuman stem cell research. At least, they do if you take the view that life begins at conception rather than birth, because research is done using early-stage embryos, or more specifically the stem cells extracted from them. The embryos die during this process - though technology is being developed to prevent this. The German parliament, the Bundestag, has introduced a law that places strict limits on this research. For instance, scientists can only use stem cell lines that were imported before May 1, 2007, a restriction meant to hinder the production of stem cells, and therefore the death of embryos, as a result of demand from Germany. Patent rows Some German scientists want to patent the results and developments they have invented through their stem cell research, and the Federal Court of Justice (BGH) pronounced a verdict on this legal question … Continue reading →